The views and opinions expressed in this blog post are those of the individual author(s) and contributors, and do not necessarily reflect the official policy or position of NeoGenomics, Inc. or any of its affiliates.
Oncology View
Welcome to Oncology View - A New Resource for Oncology Professionals
NeoGenomics is launching an oncology-specific blog to help keep you at the forefront of innovation in cancer care. The goal is to provide busy oncology professionals and pharma business partners with concise, practical updates that support Oncology practices and therapy commercialization.
PRODUCT ANNOUNCEMENT
We’re excited to announce the launch of the PanTracer portfolio. Comprehensive genomic profiling (CGP) that empowers precision therapy decisions for confident, real-time treatment decisions. Whether you’re selecting approved targeted therapies or exploring clinical trials, working from a liquid or tissue biopsy, PanTracer ensures that you’re equipped with the insights you need.
PanTracer Tissue, the next evolution of Neo Comprehensive - Solid Tumor, offers a tissue-based CGP approach, providing deep insights into tumor genomics from solid-tumor biopsy samples, helping oncologists make precise, actionable therapy decisions.
PanTracer LBx is a liquid biopsy test that delivers comprehensive, clinically actionable insights from a simple blood draw. PanTracer LBx is a liquid biopsy test that delivers comprehensive, clinically actionable insights from a simple blood draw. It empowers real-time decision-making, especially in patients for whom tissue biopsies are not feasible.
PanTracer Tissue + HRD is a single, advanced assay designed specifically for ovarian cancer, uniquely combining Comprehensive Genomic Profiling (CGP) and HRD assessment in one streamlined solution.
INDUSTRY UPDATES
Guidelines are a trusted resource that help oncologists cut through the complexity of today’s diagnostic landscape. By aligning testing strategies with recommendations—and staying current with regular updates—clinicians can ensure their diagnostic choices reflect the most relevant biomarkers, therapies, and evidence available today.
Multiple Myeloma minimal residual disease (MRD) testing guideline update
Key features of NeoGenomics’ assay include:
- Companion Diagnostic Indication: Developed in accordance with FDA guidance and validated for use with MET-targeted therapies.
- Fast Turnaround: Delivers results within 48 hours to enable timely, informed clinical decisions.
- Validated Performance: Designed for use with tumor tissue samples to detect MET protein overexpression.
- Integrated NSCLC Offering: Complements NeoGenomics’ broader PanTracer™ portfolio, including genomic and immuno-oncology markers.
The c-MET CDx for NSCLC assay is now available as part of NeoGenomics’ comprehensive NSCLC testing portfolio. Its addition supports the growing use of MET-directed therapies and reflects ongoing efforts to align diagnostic services with emerging standards in precision cancer care.
Featured tests
NEO PanTracer Tissue (formerly Neo Comprehensive - Solid Tumor)
Formerly Neo Comprehensive - Solid Tumor. NGS comprehensive genomic profile targeting 517 genes in DNA and RNA for SNVs, InDels, CNVs, RNA fusions/splice variants with MSI and TMB for pan-solid tumors.
NEO PanTracer LBx
Liquid biopsy NGS comprehensive genomic profile targeting 514 genes for SNVs, InDels, CNVs, and fusions with MSI-High and bTMB for advanced stage pan-solid tumors.
c-MET CDx for NSCLC
The c-MET tyrosine kinase receptor, normally expressed by epithelial cells, is overexpressed and amplified in a variety of human tumors, including non-small cell lung carcinoma (NSCLC).
Sign up for NeoNews
Sign up for NeoNews for exclusive access to new test announcements, clinical trial opportunities, and upcoming trade shows. Everything you need to know as a valued NeoGenomics customer, delivered right to your inbox.